Wang, X.Chen, C.Xie, C.Huang, W.Young, R.L.Jones, K.L.Horowitz, M.Rayner, C.K.Sun, Z.Wu, T.2025-07-142025-07-142022Diabetes, Obesity and Metabolism, 2022; 24(6):1134-11421462-89021463-1326https://hdl.handle.net/2440/145919Aim: To determine the serum bile acid (BA) response to 75-g oral glucose in individuals without diabetes, and whether this is attenuated in patients with ‘early’ type 2 diabetes (T2D) and related to the glycaemic response at 2 hours in either group. Methods: Forty newly diagnosed, treatment-naïve Han Chinese T2D subjects and 40 age-, gender-, and body mass index-matched controls without T2D ingested a 75-g glucose drink after an overnight fast. Plasma glucose and serum concentrations of total and individual BAs, fibroblast growth factor-19 (FGF-19), total glucagon-like peptide-1 (GLP-1), and insulin, were measured before and 2 hours after oral glucose. Results: Fasting total BA levels were higher in T2D than control subjects (P < .05). At 2 hours, the BA profile exhibited a shift from baseline in both groups, with increases in conjugated BAs and/or decreases in unconjugated BAs. There were increases in total BA and FGF-19 levels in control (both P < .05), but not T2D, subjects. Plasma glucose concentrations at 2 hours related inversely to serum total BA levels in control subjects (r = –0.42, P = .006). Total GLP-1 and the insulin/glucose ratio were increased at 2 hours in both groups, and the magnitude of the increase was greater in control subjects. Conclusions: The serum BA response to a 75-g oral glucose load is attenuated in patients with ‘early’ T2D, as is the secretion of FGF-19 and GLP-1, while in individuals without T2D it correlates with 2-hour plasma glucose levels. These observations support a role for BAs in the regulation of postprandial glucose metabolism.en© 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.bile acids; fibroblast growth factor-19; glucagon-like peptide-1; postprandial glycaemia; type 2 diabetesHumansDiabetes Mellitus, Type 2Bile Acids and SaltsInsulinGlucoseBlood GlucoseFibroblast Growth FactorsGlucagon-Like Peptide 1Journal article10.1111/dom.146832024-05-06604909Xie, C. [0000-0002-0054-9269]Huang, W. [0000-0001-9400-3840]Young, R.L. [0000-0001-5116-4951] [0009-0004-8274-9863]Jones, K.L. [0000-0002-1155-5816]Horowitz, M. [0000-0002-0942-0306]Rayner, C.K. [0000-0002-5527-256X]Wu, T. [0000-0003-1656-9210]